Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment HAART on Immune Functions Relevant for MAC and Other Opportunistic Infections
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-10-29
85
Participants Needed
26
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection.
HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.
CONDITIONS
Brief Title
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
Inclusion Criteria
You may be eligible for this study if you:
Are HIV-positive.
Have a CD4 count under 50 cells/mm3 or between 100 and 250 cells/mm3 within 30 days of study entry.
Have at least one symptom (e.g., fever, diarrhea, or weight loss) suggestive of MAC infection.
Have MAC infection with 7 days or less of MAC treatment.
Have an HIV blood level greater than 10,000 copies/ml within 30 days of study entry.
Are 18 years of age or older.
Exclusion Criteria
You will not be eligible for this study if you:
Have any active infection (except for MAC in Group 2 patients) or any cancer.
Are unable to follow an acceptable anti-HIV drug regimen (Groups 2 and 3).
Are pregnant or breast-feeding.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies
Long-Term Follow-Up Study of HIV-Infected Individuals from HIV-NAT Trials to Evaluate Clinical Outcomes and Treatment Effects
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Phase III Study Comparing Cabotegravir and Rilpivirine Ultra Long-Acting or Long-Acting Treatments in Adolescents and Adults With Suppressed HIV
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study.